Heymach, J. V., Stewart, R., Harpole, D. H., Mitsudomi, T., Taube, J. M., Galffy, G., Garbaos, G., Biswas, B., Domine, M., Massuti, B., Winder, T., Mukhametshina, G., Luong, D. V., Cid, J. R. R., Fouad, T. M., Chen, A., Mortazavi, A. M., Zhu, Z., Xiong, H., Reck, M. (2026). Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8015